Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.

Status: No longer recruiting

Protocol number: NO20254

Sponsor: Hoffmann-La Roche Inc

Company division: Pharmaceutical

Official Scientific Title: A Randomized, Open Label Trial to assess the Steady State Pharmacokinetics of Avastin given with either XELOX or FOLFOX-4 in Patients with Metastatic Colorectal Cancer

Brief summary: This 2 arm study will compare the pharmacokinetics and safety of Avastin at steady state under 2 different dosing regimens, in combination with XELOX (oxaliplatin + Xeloda) or FOLFOX-4 (oxaliplatin, leucovorin and 5-fluorouracil). Patients randomized to the XELOX arm will receive Avastin (7.5mg/kg iv) on Day 1 of each 3 week cycle; patients randomized to the FOLFOX-4 arm will receive Avastin (5mg/kg iv) on Day 1 of each 2 week cycle. The anticipated time on study treatment is 3-12 months, and the target sample size is <100 individuals. Target sample size is 60.

Study phase: III

Study type: Interventional; Treatment; Randomized; Open Label; Active; Parallel; Pharmacokinetics study

Condition: Colorectal Cancer

Intervention type: Drug

Intervention name: bevacizumab [Avastin]

Primary outcome: 1. Steady state AUC, Cmax, Cmin, Tmax, CL, V and t1/2 of bevacizumab. Time frame: Cycle 5 for XELOX arm, cycle 7 for FOLFOX arm.

Key secondary outcomes: 1. AEs, laboratory parameters. Time frame: Throughout study

Inclusion criteria:

  • adult patients, >=18 years of age;
  • adenocarcinoma of the colon or rectum, with metastatic or locally advanced disease;
  • >=1 target lesion.

Exclusion criteria:

  • patients who have previously received systemic treatment for advanced or metastatic disease;
  • patients who have received adjuvant treatment for non-metastatic disease in past 3 months;
  • previous therapy with oxaliplatin or Avastin.

Gender: Males or Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Anticipated start date: August, 2006

Trial registration date: 07/06/2006

Date last updated: 10/15/2008


Link to trial result

This trial was conducted at the following locations:

Australia

  • Fitzroy
  • Melbourne
  • Sydney

Canada

  • Brampton, ON
  • Hamilton, ON
  • Toronto, ON

New Zealand

  • Christchurch

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply